Related Experiment Video

Updated: Jul 6, 2026

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

[Organizing pneumonia associated with the use of pegylated interferon alfa]

Joan-Carles Trullas Vila1, Demetrio-Roberto Padilla López, Vicenta Bisbe Company

  • 1Servicio de Medicina Interna, Hospital Sant Jaume, Olot, Girona, Spain. jctrullas@hospiolot.com

Archivos De Bronconeumologia
|March 26, 2008
PubMed

Insights

This case report details organizing pneumonia in a hepatitis C patient treated with pegylated interferon alfa-2b. Discontinuation of the drug and corticosteroid treatment resolved the condition.

Area of Science:

  • Pulmonology
  • Hepatology
  • Pharmacology

Background:

  • Organizing pneumonia is a distinct clinicohistologic condition.
  • It can be idiopathic or secondary to infections, medical conditions, or drugs.
  • Diagnosis requires identifying organizing pneumonia foci in lung biopsies.

Observation:

  • A 49-year-old male with Hepatitis C Virus (HCV) received pegylated interferon alfa-2b.
  • The patient presented with cough, fever, dyspnea, and ground-glass pulmonary infiltrates.
  • Lung biopsy confirmed organizing pneumonia.

Findings:

  • Pegylated interferon alfa-2b was identified as the likely cause.
  • Discontinuation of the drug and initiation of corticosteroids led to symptom and infiltrate resolution.
  • This represents the second reported case of organizing pneumonia linked to this therapy.

Implications:

  • Highlights a potential adverse drug reaction of pegylated interferon alfa-2b.
  • Emphasizes the importance of considering drug-induced lung disease in patients on this treatment.
  • Suggests prompt drug withdrawal and corticosteroid use for management.

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...